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ABSTRACT
Background: Cefepime is a fourth-generation cephalosporin with broad spectrum of
activity. Cefepime continues as a major part of parenteral treatment for neutropenic
fever and hospital-associated infections including pneumonia, urinary tract infections,
skin and soft tissue infections, etc. The principle mechanism of Cefepime-induced
neurotoxicity is via inhibition of GABA-A receptors or GABA release. Neurotoxic
adverse drug reactions (ADRs) include unconsciousness, encephalopathy, aphasia,
myoclonus, seizures, and coma. Risk factors of the ADRs include renal failure, over
dosing, pre-existing brain injury, and elevated serum Cefepime levels.
Objectives: Primary objective is to determine incidence of neurotoxic ADRs related to
the use Cefepime. Secondary objective is to determine the association of dose of
Cefepime treatment and change in renal function with development of neurotoxic
ADRs.
Methods: An hospital-based retrospective cohort study was conducted for eight
months (August 2019 to March 2020), with a total of 738 patients, selected based on
pre-determined inclusion and exclusion criteria. The patients were divided into two
cohort groups: study cohort in which all the patients who received Cefepime and
reference cohort, in which all the patients who received antibiotics other than Cefepime.
Results: Out of 496 patients who were treated with Cefepime, 53 (10.7%) patients
developed ADRs. Similarly, out of 242 patients who were treated with other antibiotics,
12 (4.9%) patients developed ADRs. The age of the patients who developed ADRs with
Cefepime were 55.9±17.2 (Mean±SD) and other antibiotics were (53.95±17.1). A
significant association was seen between neurotoxicity ADRs and Cefepime use
(X2=6.641; p=0.01). Cefepime has 2.29 times increased risk of developing the ADR
than the other antibiotics (OR: 2.29; 95%CI: 1.2-4.38). Cefepime 2 grams three times
daily is the most frequent dose that caused ADRs. Daily dose of Cefepime was
4.05±1.72 (Mean±SD) grams. Out of 53 ADR patients, 36 patients were having renal
failure. Patients with renal failure have 5.5 times greater risk for developing ADRs with
Cefepime compared to patient with normal renal function (OR: 5.5; 95% CI: 2.98 10.17). Male patients have 18% more likely to develop the neurotoxicity ADR than
female patients after Cefepime use (OR: 1.18; 95%CI:0.66-2.1). The 65 neurological
ADRs experienced by the patients on Cefepime were disorientation (38.5%), loss of
consciousness (23.1%), drowsiness (18.5%), seizures (6.2%), semi-consciousness
(6.2%), delirium (3.1%) and extrapyramidal (1.5%). Similarly, 13 neurological ADRs
experienced by the patients on other antibiotics experienced were drowsiness (53.8%),
disorientation (23.1%), loss of consciousness (7.7%), seizures (7.7%), delirium (7.7%).
The calculated number needed to harm (NNH) for Cefepime was 17.2.
Conclusion: Higher incidence of ADR is developed in Cefepime group (10.7%)
compared to the other antibiotics group (4.9%). Risk of developing neurotoxicity ADRs
by prescribing Cefepime is 2.29 times higher than other antibiotics. The common
neurotoxicity ADRs with Cefepime include loss of consciousness, disorientation,
seizure, extrapyramidal, alter sensorium, drowsiness and delirium. Renal failure is a
risk factor for neurotoxicity ADRs. Male have more likely to develop the ADRs
compared to female after Cefepime use. NNH shows that on average 17 patients would
have to receive Cefepime for one additional patient to develop the ADR.

INTRODUCTION

1. INTRODUCTION
Cefepime is a broad - spectrum antibiotic, classified as fourth generation cephalosporin
which was approved for clinical use in 1996 1. Cefepime continues a vital part of
parenteral treatment for neutropenic fever and hospital-associated infections including
pneumonia, urinary tract infections(UTIs), skin and soft tissue infections, and others.
Most importantly the antibiotic has potent broad-spectrum coverage with antipseudomonal activity and reasonable stability towards certain extended-spectrum βlactamases. It is recommended as the drug of choice for a wide array of infections such
as

Klebsiella

pneumonia,

Enterobacteriaceae, Pseudomonas

aeruginosa, Staphylococcus aureus, hospital-acquired pneumonia, febrile neutropenia,
sepsis with septic shock, UTIs, persistent cough and fever specially1. The neurotoxic
effects of Cefepime were first reported in 19992. When the drug was initially approved,
data related to safety was relatively favourable, and neurotoxicity adverse events
reported were only 3 seizures among 2000 patients, with no strong evidence of
causality. Nevertheless, after subsequent years, prescribing in critically ill patients was
challenged due to higher mortality rate in patients with Cefepime. The antibiotic causes
a wide range of neurological adverse drug reactions (ADRs) such as confusion,
disorientation, hallucination, alteration of sensorium, seizure like symptoms and so on1.
The principle mechanism of Cefepime causing neurotoxicity is via inhibition of the
GABA-A receptors or inhibition of GABA release 3-4.

The risk factors of neurotoxicity with cephalosporins are the advanced age, renal
impairment, preexisting CNS disease, and an excess amount of medication in the blood
stream.5 Cefepime induced neurotoxicity mostly occurs in renal failure patients, who
have been administrated with Cefepime without dose adjustment. However, this
toxicity may also happen in patients receiving appropriate doses, based on their renal
function status and even in patients who have appropriate renal functioning.
Approximately 85% of Cefepime excreted unchanged form in urine. The terminal half
- life of the antibiotic is around 2 hours in a person with normal renal function. The half
- life of the drug may increase to 13.5 hours as renal function declines to end stage 4-15.
Therefore, in renal failure patients, Cefepime will be accumulated in both the blood as
well as cerebrospinal fluid and finally reach toxic levels 3. Cefepime-induced

1

neurotoxicity is a reversible phenomenon if early recognize and discontinue the
Cefepime. However, based on the available evidence, Drug and Food Administration
(FDA) did not decide Cefepime is unsafe. The purpose of the study was to investigate
the incidence and neurological ADRs related to Cefepime and its associated factors.

2. NEED FOR THE STUDY
Cefepime is one of the fourth generation cephalosporine which has been used
frequently against both Gram-positive and Gram-negative bacteria related infections. It
is first choice drug for treatment of febrile neutropenia, sepsis, infections with
Klebsiella

pneumonia,

Enterobacteriaceae, Pseudomonas

aeruginosa

and Staphylococcus aureus; and UTIs. Cefepime can cause various neurological
toxicity which include adverse drug reactions (ADRs) such as consciousness,
disorientation, sensorium alternation, seizures, hallucination, etc. However, most of the
time, the ADRs related to Cefepime may be over-looked. Therefore, a study which
aims to investigate the incidence of ADRs and its risk factors after Cefepime use, is a
need of the hour.

2

AIMS & OBJECTIVES
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3. AIMS & OBJECTIVES

Aim: To investigate the incidence and types of Cefepime-induced neurotoxicity and
determine different factors associated with neurotoxicity after Cefepime therapy.

Primary objective:


To investigate neurotoxic adverse drug reaction related to the use of Cefepime.

Secondary objective:


To determine the association of dose of Cefepime with development of
neurotoxic ADRs.



To determine the risk of development of the ADRs with renal function after
Cefepime use.

4

METHODOLOGY
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4. METHODOLOGY
4.1 Study Site: The study was conducted in the Department of Medicine,
Kasturba Hospital (KH), Manipal, a tertiary care hospital in SouthIndia.

4.2 Study design: Retrospective cohort study.
4.3 Study period: Eight months’ period (August 2019 - March 2020)
4.4 Sample Size: Study cohort: 496 patients
Reference cohort: 242 patients

4.5 Study criteria:
Inclusion criteria:


Above 18 years’ old



Both genders



Newly prescribed Cefepime for the infections for study group



Other antibiotics that prescribed in similar infectious disease for reference group

Exclusion Criteria:


Incomplete medical records

4.6 Data source:
The study participants broadly represent the South-Indian population. All relevant data
was obtained from the hospital database (including medical files) of the patients treated
with Cefepime or other antibiotics during the hospital stay.

4.7 Study materials:
Case Report Form (CRF) - To collect patients’ clinical and treatment data
(demographics, risk factors, treatment regimen, lab data & other clinical
investigations, antibiotics, duration and frequency of antibiotics).

6

4.8 Operation modality:
▪ Ethical clearance was obtained from the Institutional Ethics Committee (IEC)
of Kasturba Medical College and Kasturba Hospital, Manipal (IEC
No:664/2019).
▪ A standard Case Report Form (CRF) was designed to record patient data
(demographics, risk factors, prescription, lab data & other clinical
investigations, antibiotics, duration and frequency of antibiotic).

4.9 Methods:
A hospital-based retrospective cohort study was conducted for 8 months (August 2019
to March 2020) in Kasturba Hospital, Manipal, a 2032-bed tertiary care teaching
hospital in Udupi district, Karnataka, India. The study was conducted after receiving
approval from the Institutional Ethics Committee (IEC) of Kasturba Medical College
and Kasturba Hospital, Manipal (IEC reference No.664/2019 dated 10.09.2019)
[Appendix- I]. The data were collected based on rules of the Declaration of Helsinki of
1975, revised in 2013. A total of 496 patients who were admitted during January 2016
to August 2019 in General Medicine Unit of the hospital and treated with Cefepime
were selected based on the inclusion criteria. The treatment patterns in patients
prescribed with Cefepime and indication for prescribing Cefepime were identified. This
group was considered as study cohort. For the reference cohort, the patients with same
diagnosis of infectious diseases who were prescribed other antibiotics. Comparison of
the incidence of neurological ADRs between these two groups were performed.

7

Figure 1: Study Flow Chart

Screening of Hospital Inpatient Database

Selection of patients prescribed with Cefepime/other
antibiotics cases in Jan 2016-Aug 2019 based on the study
criteria.

Subjects with Cefepime
(Study Cohort)

No of subject
with the
ADRs

No of subject
without the
ADRs

Subjects with other
antibiotics
(Reference Cohort)

No of subject
without
ADRs

No of subject
without
ADRs
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4.10 Statistical methods:
Data analysis was performed using the Statistical Package for Social Sciences (IBM
SPSS) version 20.0. Cross-tabulation was used to calculate the incidence of ADRs.
Initially, Odds Ratio (OR) and Chi-square (X2) value was calculated to identify the risk
factors associated with the incidence of ADRs among the groups. Logistic regression
was performed to analyse the association between risk factors such as renal failure with
development of the ADRs, and to obtain an adjusted odds ratio at 95% CI. A p-value <
0.05 was considered statistically significant for all the statistical analysis.

9

RESULTS
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5. RESULTS

5.1 Demographic Characteristics of the Patients
A Total number of 738 patients who were admitted during August 2019 to March 2020
were included in the study. Patients prescribed with Cefepime (Study Cohort) were 496
and patients with antibiotic other than Cefepime were 242 (Reference Cohort).

Tablet 1: Demographic characteristics of the patients (N=738)
Demographic
parameters

Study Cohort
(n=496)

Reference Cohort
(n=242)

Statistical test

Age (Mean ± SD)

55.9 ± 17.2

53.9 ±17.1

t= -1.44
p = 0.15

Gender
Male

282 (56.8%)

143 (59%)

X2=0.33

Female

214 (43.1%)

99 (41%)

p =0.56

14.04 ± 9.6

9.93 ± 7.9

t=-5.79

12(1-59)

8(1-64)

Duration of
hospitalization
(Days)
Median (IQR)

p< 0.001

ADRs: Adverse drug reactions; X2 : Chi-square; t: Independent t test; p: Probability

Mean age of the patients in study cohort and control cohort is 55.90 ± 17.2 and 53.95
±17.1, respectively [Table 1]. Marjory of the patients were males in both study cohort
(56.8%) and reference cohort (59%). There is no statistically significant difference in
the mean age (t= -1.44; 0.15) and gender (X2=0.33; p =0.56) between both cohorts. On
the other hand, there is a statistically significant difference between mean duration of
hospitalization between both cohorts ( t=-5.79; p< 0.001)
.
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Figure 2: Gender-wise distribution of adverse drug reactions in both the cohorts
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Among the patients who developed ADR in both study cohort (n=53) and reference
cohort (n=12) were males (32; 60.4% vs 8;66.7%) [Figure 2]. Out of 282 male patients
in study cohort, 32 (11.3%) were developed the ADRs, whereas out of 143 male
patients in reference cohort, 8 (5.6 %) were developed the ADRs. Similarly, out of 214
female patients in study cohort, 21 (9.8%) were developed the ADRs, whereas out of
99 female patients in reference cohort, 4 (4.0 %) were developed the ADRs.

Figure 3: Age group-wise distribution of adverse drug reactions in study cohort
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The incidence of the ADR was higher in the age group 41-50 years (24.5%), followed
by age groups 51-60 (20.8%), 71-80 (20.8%), 61-70 (16.9%) and 81-90 (11.3%) in
study cohort [Figure 3]. On the other hand, incidence of ADR < 40 years of age patients
were predominantly very low (9.4%) in study cohort.

Figure 4: Age group-wise distribution of adverse drug reactions in reference
cohort
6
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The incidence of the ADR was higher in the age group 51-60 years (41.6 %), followed
by age groups 61-70 (33.3 %) in reference cohort [Figure 4]. On the other hand,
incidence of ADR < 40 years of age patients were predominantly very low (8.3%) in
reference cohort.
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Table 2: Summary characteristics of the study population based on ADR(N=738)
Patient characteristics

Study Cohort (n=496)

Reference Cohort (n=242)

ADR present

ADR absent

ADR present

ADR absent

Number of patients

53 (10.7%)

443 (89.3%)

12 (4.9%)

230 (95.0%)

Age (Years), Mean ± SD

58.34±16.7

55.61±17.72

60.75±15.8

53.60±17.14

32 (11.3%)
21 (9.8%)

250 (88.7%)
193 (90.2%)

8 (5.6%)
4 (4.0%)

135(94.4%)
95(96.0%)

0 - 10
11 - 20
21 - 30
31 - 40
41 - 50
51 - 60
61 - 70
71 - 80
81 - 90

--1(1.9%)
2(3.8%)
2 (3.8%)
13 (24.5%)
11 (20.7%)
9 (17.0)
11 (20.8%
4 (7.5%)

--17 (3.8%)
34(7.7%)
41(9.2%)
61(13.8%)
92(20.8%)
105(23.7%)
72(16.3%)
21(4.7%)

--1(8.3%)
------5(41.7%)
4(33.4%)
1(8.3%)
1(8.3%)

--5(2.2%)
29(12.6%)
21(9.1%)
38(16.5%)
44(19.1%)
52(22.6%)
37(16.2%)
4(1.7%)

Duration of hospitalization
(days), Median (IQR)

17(3-37)

11(1-59)

12.5(4-40)

8(1-64)

Gender
Male
Female
Age group (Years)

ADRs: Adverse drug reactions; SD: Standard deviation; IQR: Interquartile range

A total of 10.7 % (53) out of 496 study cohort had developed neurotoxicity ADRs,
whereas, in the reference cohort, only 4.9% (12) of 242 patients had developed the
ADRs. In the patients who developed ADRs, higher incidence was observed among
males compared to female in both study cohort (11.3% vs 9.8%) and reference cohort
(5.6% vs 4.0%). The incidence of ADRs was predominantly more after 40 year of age
for study cohort (90.5%) and after 50 year of age for reference cohort (91.7%). Median
duration of hospitalization for patients developed ADR was 17(IQR: 3 to 37) days in
study cohort, whereas 12.5 (IQR: 4 to 40) days in reference cohort [Table 2].
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5.2 Prescription details of the antibiotics
5.2.1 Indications for the use of antibiotics in the study population
Table 3: Indications for the use of antibiotics in the study population
Sl.No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Indication
Pneumonia
Fever
Neutropenia
Sepsis and Septic shock
UTI (E. coli)
Empirically (Including cough)
Pancytopenia
Post-operation
URTIs
Leukopenia
Bronchitis
Pseudomonas aeruginosa infections
E.coli infections (other than UTI)
Meningitis
Others
Total

Cefepime
156(31.5%)
68(13.7%)
58(11.7%)
53(10.7%)
47(9.5%)
23(4.6%)
19(3.8%)
11(2.2%)
10(2.0%)
10(2.0%)
10(2.0%)
10(2.0%)
7(1.4%)
2(0.4%)
12(2.4%)
496(100%)

Other antibiotic
78(32.2%)
32(13.2%)
30(12.4%)
27(11.2%)
24(9.9%)
11(4.5%)
10(4.1%)
5(2.1%)
5(2.1%)
5(2.1%)
5(2.1%)
5(2.1%)
4(1.7%)
1(0.4)
--242(100%)

E.coli: Escherichia coli; UTI: Urinary tract infections; URTIs: Upper respiratory tract infections

Pneumonia (156; 31.5%) was the most common indication for the use of Cefepime in
study cohort, followed by fever (68;13.7%), neutropenia (58;11.7%), sepsis and septic
shock (53;10.7%), UTI (47;9.5%), and empirically (23; 4.6%), etc. Similarly,
pneumonia (78; 32.2%) was the most common indication for the use of other antibiotics
in reference cohort, followed by fever (32; 13.2%), neutropenia (30;12.4%)), sepsis and
septic shock (27;11.2%) and UTI (24; 9.9%) and empirically (11; 4.5%), etc [Table 3].

5.2.2 Frequency of different doses of Cefepime prescribed in study cohort
The most commonly prescribed dose of Cefepime was 2 grams (57.7%), followed by 1
gram (41.1%), whereas less commonly dose prescribed dose was 0.5 gram (1.2%)
[Figure 5]. Mean±SD of daily dose of Cefepime was 4.05±1.72 grams (Min=1,
Max=6).
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Figure 5: Frequency of different doses of Cefepime prescribed in study cohort

No. of Patients/Frequency of Cefepime
prescription

(N=496)

286(57.7%)

204(41.1%)

6 (1.2%)

0.5G

1G
Dose

2G

G: Gram
Table 4: Association between different doses of Cefepime and development of
the adverse drug reaction
Dose

No ADRs (%)

ADRS (%)

Total

5 (83.3%)

1 (16.7%)

6 (100%)

1 Gram

182(89.2%)

22 (10.8%)

204 (100%)

X2=0.239

2 Gram

256 (89.5%)

30 (10.5%)

286(100%)

p =0.888

Total

443 (89.3%)

53 (10.7%)

496 (100%)

0.5 Gram

Statistical test

ADRs: Adverse drug reactions; X2: Chi-square; p: Probability
There was no statistically significant association between neurotoxicity ADRs and
Cefepime doses (X2=0.239; p=0.888). However, 2 grams of Cefepime was the most
frequently caused the neurotoxicity [Table 4].
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5.2.3 Frequency of other antibiotic prescribed in reference cohort
The reference cohort consists of 242 patients, who were prescribed with 14 different
antibiotics. Some patients were administered with more than one antibiotic. The
frequency of each antibiotic prescription is presented below [Tablet 5].
Table 5: Frequency of other antibiotic prescribed in reference cohort
Sl No.

Other antibiotics

Frequency (%)

1

Piperacillin-tazobactam

59 (16.9%)

2

Meropenem

49 (13.6%)

3

Meropenem-sulbactam

4

Cefoperazone-sulbactam

5

Ceftriaxone

6

Amoxicillin-clavulanic acid

7

Imipenem

2 (0.6%)

8

Amikacin

14 (3.9%)

9

Cefuroxime

2 (0.6%)

10

Vancomycin

1 (0.3%)

11

Tigecycline

13 (3.6%)

12

Azithromycin

13

Ceftazidime

4 (1.1%)

14

Cefotaxime

1 (0.3%)

Total

2 (0.6%)
35 (9.7%)
112 (31.1%)
24 (6.7%)

42 (11.7%)

360 (100%)

242 patients were prescribed with a total of 360 antibiotics in reference cohort, which
indicated that the average number of antibiotic per patient was 1.5.

5.3 Incidence of adverse drug reaction in both the cohorts
It was found that the incidence of ADRs was higher in people who were on the
Cefepime therapy when compared those who were on other Antibiotics drugs.
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Table 6: Association between incidence of the adverse drug reactions with
antibiotic prescribed
Antibiotic

ADRS (%)

No ADRs (%)

Total

Statistical test

Cefepime

53 (10.7%)

443 (89.3%)

496 (100%)

Other antibiotics

12 (4.9%)

230 (95.0%)

242 (100%)

Total

65 (8.8%)

673 (91.2%)

738 (100%)

X2=6.641
p =0.01
OR=2.29
95%CI: 1.2-4.38

2

ADRs: Adverse drug reactions; X : Chi-square; p: Probability; OR: Odds ratio; CI: Confidence interval

Higher incidence (10.7%) of ADR were present in Cefepime group compared to other
antibiotics group (4.9%) [Table 6]. A statistically significant association was found
between neurotoxicity ADRs and Cefepime use (X2=6.641; p=0.01). The risk of
developing neurotoxicity ADRs with Cefepime is 2.29 times higher than other
antibiotics (OR=2.29; 95%CI: 1.2-4.38)

5.4 Incidence of adverse drug reactions among different doses of
Cefepime

Figure 6: Incidence of adverse drug reactions among different doses of
Cefepime
0.5Gram (
1;1.9%)

2Gram (30; 56.6%)
1Gram (22; 41.5%)

Out of 53 patients who developed ADRs with Cefepime, 30 (56.6%) were received 2
grams of Cefepime, 22(41.5%) were received 1gram of Cefepime and 1(1.9%) were
received 0.5 gram of Cefepime [Figure 6].
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5.5 Incidence of adverse drug reactions among other antibiotics
Out of 12 patients who developed ADRs with other antibiotics, 5 (41.7%) patients each
were developed ADRs with Piperacillin-tazobactam and Meropenem. Whereas, 1
(8.3%) patients each were developed ADR with Ceftriaxone and Cefoperazonesulbactam [Figure 7].

Figure 7: Incidence of adverse drug reactions among other antibiotics
CefoperazoneCeftriaxone sulbactam
(1;8.3%)
(1;8.3%)

Piperacillintazobactam
(5;41.7%)

Meropenem
(5;41.7%)

Piperacillin-tazobactam

Meropenem

Ceftriaxone

Cefoperazone-sulbactam

5.6 Frequency of Cefepime prescription with advrese drug reaction
18 (33.9%) patients who developed the ADR were prescribed with 2 gram of Cefepime
three times daily (TID). 11 (20.7%) patients each were developed the ADR with 1
gram of Cefepime two times daily (BID)and three times daily (TID) [Table 7].
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Table 7: Frequency of Cefepime prescriptions with adverse drug reaction
Cefepime
Dose

Frequency of
Dose

0.5 Gram

1 Gram

2 Grams

OD

Patients with
renal failure
(%)
---

Patients with
normal renal
function (%)
---

No. of patients
(%)

BID

1(1.9%)

---

1 (1.9%)

TID

---

---

--

OD

---

---

--

BID

7 (13.2%)

4 (7.5%)

11 (20.7%)

TID

8 (15.1%)

3 (5.6%)

11 (20.7%)

OD

3 (5.6%)

1 (1.9%)

4 (7.5%)

BID

6 (11.3%)

2 (3.8%)

8 (15.1%)

TID

11(20.7%)

7 (13.2%)

18 (33.9%)

Total

36 (67.9%)

17 (32.1%)

53 (100%)

---

OD: Once dialy; BID: bis in die; TID: ter in die

5.7 Incidence of antibiotic- induced adverse drug reactions among
renal failure patients
Figure 8: Incidence of Cefepime-induced adverse drug reactions based on renal
function
40

36(67.9%)

No. of Patients with ADRs

35
30
25
20

17(32.1%)

15
10
5
0
Renal Failure

Normal Renal Function

Out of 53 patients who developed Cefepime- induced ADRs, 36 patients (67.9%)
have renal failure [Figure 8].

20

Figure 9: Incidence of adverse drug reaction with other antibiotics based on
renal function
8

7(58.3%)

No. of patients with ADR

7
6
5

5(41.7%)

4
3
2
1
0
Renal Failure

Normal Renal

Out of 12 patients who developed ADRs with other antibiotics, 5 patients (41.7%)
have renal failure [Figure 9].

5.8 Onset time for development of adverse drug reaction after
antibiotic use
Table 8: Onset time for development of adverse drug reaction in both cohorts
Onset time of ADRs

Cefepime

Other antibiotics

Statistical Test*

Minimum Days

2

4

t= 4.092

Maximum Days

16

23

p <0.001

Mean(±SD)

7.3 ± 3.4

12.5 ± 6.1

*Independent t test; p: Probability; SD: Standard deviation

The mean onset time for developing ADRs after Cefepime use is 7.3 ± 3.4 days,
whereas mean onset time for developing ADRs after other antibiotic use is 12.5±6.1
[Table 8]. There is a statistically significant difference between mean onset time for
development of ADRs between both cohorts (t= 4.092; p <0.001).
.
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5.9 Classification of neurotoxicity adverse drug reaction
Table 9: Frequency and type of adverse drug reactions in both cohorts
Type of ADRs

Cefepime

Other antibiotics

Loss of consciousness

15 (23.1%)

1 (7.7%)

Disorientation

25 (38.5%)

3 (23.1%)

Seizures

4 (6.2%)

1 (7.7%)

Extrapyramidal

1 (1.5%)

---

Alter sensorium

2 (3.1%)

---

12 (18.5%)

7 (53.8%)

Delirium

2 (3.1%)

1 (7.7%)

Semi-consciousness

4 (6.2%)

---

65 (100%)

13 (100%)

Drowsiness

Total
ADRs: Adverse drug reactions

In the study cohort, a total of 65 ADRs were experienced by 53 patients. Of these, 12
patients were developed two ADRs. Disorientation (25; 38.5%) was the most common
neurotoxicity observed in Cefepime group. In the reference cohort, a total of 13 ADRs
were experienced by 12 patients. Of these, only one patient was developed two ADRs.
Drowsiness (7; 53.8%) was the most common neurotoxicity observed in other
antibiotics group [ Table 9].

5.10 Risk estimation for development of the adverse drug reaction
5.10.1 Renal function

Table 10: Association between Cefepime-induced adverse drug reaction and
renal failure
RF

ADR

No ADR

Total

Statistical Test*

Yes

36 (22.6%)

123 (77.4%)

159 (100%)

OR = 5.51

No

17 (5.0%)

320 (95.0%)

337 (100%)

95%CI = 2.98-10.17

Total

53 (100%)

443 (100%)

496 (100%)

* Logistic Regression; ADRs: Adverse drug reactions; CI: Confidence Interval; OR: Odds ratio; RF:
Renal failure
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The risk for development of Cefepime-induced neurotoxicity ADR in patients with
renal failure are 5.5 times higher than the patients with normal renal function (OR:
5.5; 95% CI: 2.98-10.17) [Table 10].

Table 11: Association between adverse drug reaction and renal failure in
reference cohort
RF
ADR
No ADR
Total
Statistical Test*
Yes

5(8.2%)

56 (91.8%)

61(100%)

OR: 2.22

No

7 (3.9%)

174 (96.1%)

181(100%)

95%CI:0.68-7.27

Total

12(100%)

230 (100%)

242(100%)

* Logistic Regression; ADRs: Adverse drug reactions; CI: Confidence Interval; OR: Odds ratio; RF:
Renal failure

The risk for development of neurotoxicity ADR with other antibiotics in patients with
renal failure are 2.22 times higher than the patients with normal renal function (OR:
2.22; 95% C I: 0.68-7.27) [Table 11].

5.10.2 Gender
Table 12: Association between Cefepime-induced adverse drug reaction and
gender
Statistical Test*
Gender
ADR
No ADR
Total
Male

32 (11.3%)

250 (88.7%)

282 (100%)

Female

21 (9.8%)

193 (90.2%)

214 (100%)

Total

53(100%)

443 (100%)

496 (100%)

OR: 1.18
95%CI:0.66-2.1

*Logistic Regression; ADRs: Adverse drug reactions; CI: Confidence Interval; OR: Odds ratio

Male patients have 18% more likely to develop the neurotoxicity ADR compared to
female patients after Cefepime use (OR: 1.18; 95%CI:0.66-2.1) [Table 12]
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5.11 Causality assessment of adverse drug reaction in both cohorts
Table 13: Causality assessment of adverse drug reaction in both cohorts

Scale

Category

Study Cohort
(No. of ADR cases)
---

Reference Cohort
(No. of ADR cases)
---

Probable/Likely

10(18.9%)

---

Possible

43(81.1%)

12 (100%)

Definite

---

---

Probable

5(9.5%)

---

Possible

48(90.5%)

12 (100%)

Certain
WHO-UMC
Criteria

Naranjo’s
Scale

ADRs: Adverse drug reactions
In study cohort, the ADRs of 48 (90.5%) patients were categorized under “possible”
based on Naranjo’s scale. On the other hand, the ADRs of 43(81.1%) patients were
categorized under “possible” based on WHO-UMC criteria [Table 13]. Whereas, in
reference cohort, the ADRs of all patients (12;100%) were categorized under “possible”
based on Naranjo’s scale as well as WHO-UMC criteria.

5.12 Number Needed to Harm (NNH)
When an experimental treatment is detrimental, the term ‘number needed to harm’ is
often used. This is the number of people you would need to treat with a specific
intervention for a given time to cause one additional adverse outcome.
When a study outcome is expressed as a percent, the NNH is the inverse of the absolute
risk increase (ARI).
ARI = EER-CER (Experiment Event Rate – Control Event Rate)
= (10.7/100 _ 4.9/100)= 0.107 _ 0.049 = 0.058
NNH= 1/ARI= 1/0.058 =17.2

The calculated NNH is 17.2, which means that on average 17 patients would have to
receive Cefepime for one additional patient to develop neurotoxicity ADR.
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DISCUSSION
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6. DISCUSSION
A retrospective cohort study was conducted in Kasturba hospital, Manipal for 8 months
(August 2019- March 2020). This study comprises 738 patients admitted from January
2016 to August 2019. Out of these 738 patients, 496 patients prescribed with Cefepime
(they were considered as study cohort) and 242 patients prescribed with other
antibiotics for similar indications (they were considered as reference cohort). This study
is first of that kind, which reported incidence of Cefepime- induced neurotoxicity ADR
in an Indian setting.
In our study, incidence of the neurological related ADR in patients with Cefepime was
found to be 10.7%, whereas incidence of the ADR in patients with other antibiotics was
only 4.9%. However, other studies have reported varying range of incidence (1% to
15%) of neurological ADRs with Cefepime

16-19

. The lower incidence of the ADRs in

other studies may be because clinicians may be overlooked the ADRs due to mild
characteristics of the neurotoxicity symptoms. A study by Lamoth et al (2010) reported
very high incidence (20%) of the ADRs 20. This is because their study populations were
febrile neutropenia patients, for them normally high dose of Cefepime was
recommended. All the patients who developed neurotoxicity ADRs were received 6
grams per day of Cefepime. A systematic review by Payne et al (2017) reported that
out of 100 patients prescribed with Cefepime, 15 (15%) had experienced of
neurological toxicity 19.
We found a significant association between neurotoxicity ADRs and Cefepime use,
which means that higher incidence of the ADRs in patients with Cefepime compared
to patients with other antibiotics (X2=6.641; p=0.01). Moreover, risk estimation shows
that Cefepime has 2.29 times higher risk of developing neurotoxicity ADRs than other
antibiotics (OR: 2.29; 95%CI: 1.2-4.38). The mean daily dose of Cefepime that
administered to patients was 4.05±1.72 (SD) gram. Fugate et al (2013) study reported
the median daily average dose of cefepime was 2.5 (IQR 2.0 to 3.5) grams17. The most
frequent dose of Cefepime that caused neurotoxicity was 2 grams three times daily.
These findings were almost similar to Lamoth et al (2010) study were all the patients
who developed neurotoxicity ADRs were received 6 grams per day of Cefepime 20.
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We have observed a male predominance in the occurrence of the ADR compared to
female among Cefepime users (11.3% vs 9.8%) as well as other antibiotics users (5.6%
vs 4.0%), because majority of the study population in the both groups were males
(56.8% vs 59%). This may be because number of male wards are more compared to
female wards in KH hospital. In Lamoth et al (2010) study all the patients who
developed Cefepime-induced neurotoxicity ADRs were males
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. In our study male

patients have 18% more likely to develop the neurotoxicity ADR compared to female
patients after Cefepime use (OR: 1.18; 95%CI:0.66-2.1). However, another study
concluded that there is no significant difference between male and female gender in the
occurrence of the ADRs 18. Occurrence of ADR were more in the age group 41-60 years
in Cefepime group and 51-60 in other antibiotics group. This may be because of the
mean age for Cefepime group is 55.9 ± 17.2 years and for other antibiotics is 53.9 ±
17.1 years. In a retrospective study by Fugate et al (2013) with adult intensive care unit
(ICU) patients treated with intravenous Cefepime, the mean age was 65.8 years (± 12.7
years)17. This difference in the mean age may be because of the change in study settings,
more aged patients may be critically ill and get admitted in ICU. Currently, the median
age of critically ill patients approaches 65 years 21. A systematic review reported
majority of the patients with Cefepime-induced neurotoxicty were elderly, with a
median of 69 years (IQR:54 to 75 years) because they are more susceptible to renal
dysfunction as well as central nervous system (CNS) adverse effects 19. In our study,
the mean age to develop the Cefepime-induced ADRs was 53.34 ± 16.7 (SD). We found
median duration of Cefepime therapy was 7 (IQR: 2 to 12) days, whereas Fugate et al
(2013) study have median treatment duration of 6 (IQR: 4 to 10) days17. In our
observation, the mean onset time for developing ADRs after Cefepime use is 7.3 ± 3.4
(SD) days, whereas Payne et al (2017) reported a median of 4 days (IQR: 2 to 6 days)
following Cefepime initiation19. We found a statistically significant difference between
mean onset time for development of ADRs between both cohorts (t= 4.092; p <0.001),
indicating that Cefepime-induced neurotoxicity has faster onset of time compared to
other antibiotics. Median duration of hospitalization for patients with the ADR was
higher for both cohorts [study cohort: 17(IQR: 3 to 37) days; reference cohort:12.5
(IQR: 4 to 40) days] compared patients without the ADR [study cohort: 11(IQR: 1 to
59) days; reference cohort: 8 (IQR: 1 to 64) days]. These findings were similar to
Giardina et al (2018) study on ADR in hospitalized patients, which reported the
duration of hospitalization was longer in patients who developed ADRs during hospital
27

stay, compared to patients without ADRs [median 12 (IQR: 8 to 17) days vs. 9 (IQR: 6
to 13) days]22.
Causality assessment of ADR according to WHO-UMC criteria scale as well as
Naranjo’s scale shows majority of the cases fall under ‘possible’ category (81.1% and
90.5%, respectively), followed by ‘probable’ (18.9% and 9.5%, respectively). On the
other hand, a previous study reported 46.7% were ‘definite’, 20% ‘probable’, and 33.3
% ‘possible’ cases17. In our study, most common neurotoxic symptom was
‘disorientation’ followed by ‘loss of consciousness’, whereas ‘loss of consciousness’
followed by ‘myoclonus’ was the most common in Fugate et al (2013) study

17

.

Similarly, Appa et al (2017) reported that the most common symptoms were loss of
consciousness, disorientation, and myoclonus18.
In our study, 32% of the patients prescribed with Cefepime had renal failure including
acute and chronic. However, in Fugate et al (2013) study, 84% of the patients were
present with renal failure in any form17. In our study, 67.9% of patients with renal
failure developed neurological ADRs, which was comparable to Fugate et al (2013)
study, where 66.7% of chronic kidney disease patients were with neurotoxicity17.
Similarly, a systematic review by Payne et al (2017) reported 80% of the patients have
renal failure19. In patients with renal failure, concentrations of Cefepime in
cerebrospinal fluid (CSF) may elevate due to competitive inhibition of active transport
of Cefepime from CSF to blood by organic acids 23,24, increase in permeability of bloodbrain barrier (BBB), and a decline in serum protein binding
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. Logistic regression

shows that renal failure patients have 5.5 times increased of risk of development of
Cefepime-induced neurotoxicity compared to patients with normal renal function.
Fugate et al (2013) observed that critically ill patients with chronic kidney disease are
particularly susceptible to Cefepime neurotoxicity

17

. However, 32.2% the patients

developed Cefepime-induced neurotoxicity despite normal renal function 26. The risk
for development of neurotoxicity ADR with other antibiotics in patients with renal
failure are 2.22 times higher than the patients with normal renal function (OR; 2.22;
95% C I: 0.68-7.27).
Finally, we calculated NNH for the Cefepime, which was found to be 17.2. This means
that on an average 17 patients would have to receive Cefepime for one additional patient
to develop the neurotoxicity ADR.
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LIMITATIONS
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7. LIMITATIONS


Since it is a retrospective cohort study, the investigators do not have access to
the many parameters which might influence the development of the ADR.



Since the study is performed only in a single center, which limits the
generalization of the results to other population.



The study did not consider the reason for the development of ADRs such as
drug interactions.



Indications for antibiotic use (Eg. Prophylactic, empirical or definite therapy)
were not mentioned.
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8. CONCLUSION
Higher incidence of the ADR is developed in the patients after Cefepime use (10.7%)
compared to the patients with other antibiotics (4.9 %) used for same conditions. The
study finds a harmful association between Cefepime use and neurotoxicity ADR.
Cefepime use is related to 2.29 times increased risk of development of the ADRs than
other antibiotics. The common neurotoxicity ADRs with Cefepime include loss of
consciousness, disorientation, seizure, extrapyramidal, alter sensorium, drowsiness and
delirium. Renal failure is a risk factor for the occurrence of the ADRs. Male have more
likely to develop the ADRs compared to female after Cefepime use. The NNH shows
that on average 17 patients would have to receive Cefepime for one additional patient
to develop the ADR. This study is first of that kind, which reported incidence of
Cefepime- induced neurotoxicity ADR in general population based on cohort-event
reporting in our settings. Physician must consider the neurological-related safety of
Cefepime before prescribing it. Their usage must be restricted to the conditions where
alternatives are not available.
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9. FUTURE DIRECTIONS


A multicentric prospective study, should be conducted to investigate the
incidence of the Cefepime-induced neurotoxicity.



Pharmacoeconomic and quality of life study should be carried out to
determine effect of the adverse drug reactions on humanistic and economic
outcomes.



Develop a prediction model for the occurrence of Cefepime-induced
neurotoxicity.
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PATIENT DATA COLLECTION FORM
ADVERSE EFFECTS OF CEFEPIME
Age:
Sex :

Weight (Kg):
BMI :

Brand Name

DOA :
DOD :

Height :

Generic Name
CEFEPIME

Cohort :
Reference/ Study

Dose

Frequency

Duration

Route

Other Antibiotics:

Indication:
Factors:
Steroids
: Yes 
Transplant Recipient renal/liver: Yes 
Renal/Hepatic Failure
: Yes 
Adverse Reaction:
System:
Symptoms:
depressed

No
No
No
Onset of ADR:

consciousness
encephalopathy
aphasia
myoclonus
Seizures
NCSE
Coma
Biochemical Investigations :
Causality Assessment:
WHO :  Certain
 Probable/Likely
 Possible
 Unlikely
 Conditional/Unclassified
 Unassessable/Unclassifiable

Naranjo :  > 9 = definite ADR
 5-8 = probable ADR
 1-4 = possible ADR
 0 = doubtful ADR
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